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Purpose: The objective of the current study was to identify the clinicopathological risk factors affecting recurrence after a 
curative resection for stage I colorectal cancer. 
Methods: We retrospectively studied 434 patients who underwent a curative resection for stage I colorectal cancer between 
January 1999 and December 2004. Postoperative oral chemotherapy was performed in 189 patients (45.3%). The follow-
ing prognostic factors were correlated with recurrence: age, gender, preoperative carcinoembryonic antigen level, location 
of tumor, T stage, size of tumor, histologic differentiation, growth pattern, and lymphovascular invasion. The median fol-
low-up duration was 65 months. 
Results: The overall recurrence rate was 4.6% (20/434). The median time to recurrence was 33 months. Two-thirds of the 
recurrence occurred more than two years after surgery. Risk factors associated with recurrence were rectal cancer (P = 
0.009), T2 stage (P = 0.010), and infiltrative growth pattern (P = 0.020). A Cox proportional hazards regression analysis 
demonstrated that the infiltrative growth pattern was an independent predictor for recurrence. Tumor cell budding was 
observed in all pathologic reviews with recurrence. 
Conclusion: Long-term follow-up is necessary for stage I colorectal patients with high risk factors like rectal cancer, T2 
stage, and infiltrative growth pattern. 
Keywords: Colorectal neoplasms; Recurrence; Risk factors
90% 5-year survival post radical resection is being achieved [3]. 
Although 10 to 13% of stage I colorectal cancer patients who un-
dergo a radical resection experience recurrence, adjuvant chemo-
therapy is generally not recommended for them because it does 
not improve their survival rate [4, 5]. The purpose of this study is 
to select clinicopathologic factors related to the recurrence among 
stage I colorectal cancer patients who undergo a radical resection.
METHODS
Among the 4.489 patients who had radical resections due to colorec-
tal carcinomas in this Department of Colorectal Surgery between 
January 1999 and December 2004, 515 patients (11.4%) were di-
agnosed with first-stage colorectal cancer on histopathologic ex-
amination. A radical resection is defined as a surgical resection 
that ligates the origin of feeding vessels and takes all lymph nodes 
between the pericolic lymph nodes and the principle lymph nodes. 
Among these 515 patients, familial adenomatous polyposis (21 
patients), hereditary non-polyposis colorectal cancer (14 patients) 
and patients who had preoperative chemoradiation therapy (46 
INTRODUCTION
Colorectal cancer is the third most prevalent cancer in South Korea, 
following gastric cancer and thyroid cancer. It accounts for 12.7% 
of all cancers, and its prevalence is increasing [1]. Because the num-
ber of early diagnoses of the stage I colorectal cancer is tending to 
increase as the number of people being screened with occult blood 
tests and colonoscopy through the national campaign for cancer 
screening has increased [2], an excellent prognosis of greater than 
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patients) were excluded, and finally 434 patients were chosen as 
subjects for this study. Retrospective analyses of clinicopathologic 
factors and of follow-up test results were conducted with prospec-
tively collected data. Among the 434 subjects, 189 had postopera-
tive oral immunochemotherapy. The surgeons decided on this for 
patients carrying a high risk of recurrence as they presented with 
evidence of lymphovascular invasion or T2 stage, poorly differen-
tiated cancer, and signet ring cell carcinomas during the surgery 
and on the pathologic diagnosis. Single oral chemotherapy (tega-
fur/uracil or doxifluridine) or one combined with an immune 
modulator (polysaccharide-k) therapy was administered for at 
least 3 months up to 12 months; 113 patients among 189 patients 
had the combined therapy.
All the subjects were categorized into the recurrence group and 
the non-recurrence group during the follow-up period, and their 
clinicopathologic factors (age, sex, preoperative carcinoembry-
onic antigen value, the location of tumor T stage [T1 or T2], the 
size of tumors, the gross finding of the tumor [fungating type or 
infiltrative type], histologic grade, lymphovascular invasion, the 
number of obtained lymph nodes, postoperative oral immuno-
chemotherapy) were compared and analyzed. The diagnosis of 
recurrence was completed by radiological or histological investi-
gation, and the time to recurrence was counted from the opera-
tion day. Local recurrence was defined as occurring when the can-
cer was recurrent in the anastomosis site or in the structure of the 
pelvic cavity (vagina, bladder, and lymph nodes located in the pel-
vic cavity), and distant recurrence was defined as occurring when 
the cancer was recurrent in the systemic lymph nodes, liver, lung, 
peritoneum, bones and brain [6]. The mean period of follow-up 
Table 2. Clinicopathologic characteristics for patients with recurrence 
(n = 20)
Characteristic Value
Time to recurrence (mo), median (range) 33 (3-71)
Site of recurrence (no. of cases)
   Local
      Presacral mass 3
      Anastomosis 2
      Pelvic wall 2
   Distant
      Liver 4
      Lung 4
      Others 4
      Combined 1
Treatment for recurrent disease (no. of cases)
   Operation & chemotherapy 5
   Chemotherapy or radiation therapy 8
   Conservative management 7
Table 1. Clinicopathologic characteristics for patients with stage I 
colorectal cancer (n = 434)
Characteristic Value
Age (yr)   60.5 (11.2)
Sex
   Male  250 (57.6)
   Female 184 (42.4)
CEA (ng/mL)    4.2 (5.1)
Location of tumor
   Colon 145 (33.4)
   Rectum 289 (66.6) 
Operation
   ICR 1 (0.2)
   RHC 30 (6.9)
   LHC 6 (1.4)
   AR 99 (22.8)
   LAR 147 (33.9)
   ULAR 72 (16.6)
   APR 77 (17.7)
   TC 2 (0.5)
T stage
   T1 132 (30.4)
   T2  302 (69.6)
Size (cm)
   <4  252 (58.1)
   <4  182 (41.9)
Growth type
   Expanding (B-I/II) 388 (89.4)
   Infiltrative (B-III/IV)  46 (10.6)
Differentiation
   WD/MD 421 (97.0)
   PD/SRC 13 (3.0)
Lymphovascular invasion
   No 390 (89.8)
   Yes  44 (10.2)
No. of harvested lymph nodes   13.1 (8.1)
Postoperative immunochemotherapy
   No 245 (56.5)
   Yes 189 (43.5)
Values are presented as mean (SD) or number (%).
SD, standard deviation; CEA, carcinoembryonic antigen; ICR, ileocecal resection; 
RHC, right hemicolectomy; LHC, left hemicolectomy; AR; anterior resection; LAR, 
low anterior resection; ULAR, ultralow anterior resection; APR, abdominoperineal 
resection; TC, total colectomy; B-I/II, Bormann type-fungating/ulcerofungating; B-
III/IV, Bormann type-ulceroinfiltrative/infiltrative; WD, well-differentiated; MD, mod-
eratelydifferentiated; PD, poorly differentiated; SRC, signet ring cell.Journal of The Korean Society of
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of all the patients was 65 months (2 to 127 months). An indepen-
dent-sample t-test for continuous variables and a chi-square test 
for nominal variables were conducted. A multivariate analysis was 
conducted for clinicopathologic factors that were judged to be 
statistically significant through a Kaplan-Meier survival analysis, 
and the Cox regression model was used for the analysis. Results 
were judged to be statistically significant when P-value was less 
than 0.05 bilaterally.
RESULTS
Table 1 summarized the clinicopathologic characteristics of the 
434 patients who were diagnosed with stage I colorectal cancer 
after a radical resection due to a sporadic colorectal carcinoma. 
Recurrence was identified in 20 (4.6%) patients during the follow-
up period, and they were classified as the recurrence group. The 
median value of the time to recurrence was 33 months (range, 3 
to 71 months). The invasion depth of the recurrent T1 stage pa-
tients was sm3. Among the 20 patients experiencing recurrence,   
5 had a reoperation and chemotherapy, 8 had chemotherapy and 
radiotherapy, and 7 had only symptom-control treatments. Of the 
20, 14 expired during the follow-up period. The mean survival 
period of the remaining 6 patients was 39 months (range, 14 to 68 
months) after the above treatments for recurrence, and only 2 pa-
tients among the 6 survived longer than 5 years. Table 2 presents 
the clinicopathologic findings, the location of recurrence, the treat-
Table 3. Univariate and multivariate analysis of prognostic factors in stage I colorectal cancer
Variable
Without recurrence  
(n = 414)
With recurrence  
(n = 20)
Univariate  
P-value
Multivariate  
P-value
 HR (95% CI)
Age (yr) 60.3 (11.3) 64.7 (8.9) 0.085
Sex 0.551
   Male 240 (96) 10 (4)
   Female 174 (94.6) 10 (5.4)
CEA (ng/mL) 4.1 (5.1) 5.1 (5.4) 0.390
Location of tumor 0.009 0.061
   Colon 143 (99.3) 1 (1.4)
   Rectum 271 (93.4) 19 (6.6)
T stage 0.010 0.064
   T1 131 (99.2) 1 (0.8)
   T2 283 (93.7) 19 (6.3)
Size (cm) 0.379
   <4  242 (96.0) 10 (4.0)
   ≥4  173 (94.5) 19 (5.5)
Growth type 0.017 0.020 3.36 (1.21-9.34)
   Expanding (B-I/II) 373 (96.1) 15 (3.9)
   Infiltrative (B-III/IV) 41 (89.1) 5 (10.9)
Differentiation 0.068
   WD/MD 403 (95.7) 18 (4.3)
   PD/SRC 11 (84.6) 2 (15.4)
Lymphovascular invasion 0.520
   No 373 (95.6) 17 (4.4)
   Yes 41 (93.2) 3 (6.8)
No. of harvested lymph nodes 13.1 (8.1) 14.0 (7.9) 0.637
Postoperative immunochemotherapy 0.181
   No 237 (96.7)  8 (3.3)
   Yes 177 (93.7) 12 (6.3)
Values are presented as mean (SD) or number (%).
HR, hazard ratio; CI, confidence interval; SD, standard deviation; CEA, carcinoembryonic antigen; B-I/II, Bormann type-fungating/ulcerofungating; B-III/IV, Bormann type-
ulceroinfiltrative/infiltrative; WD, well-differentiated; MD, moderately differentiated; PD, poorly differentiated; SRC, signet ring cell. 
Univariate analysis, Kaplan-Meier; multivariate analysis, Cox regression.Journal of The Korean Society of
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ments, and the progress of the disease for the recurrence group.
Table 3 presents a comparative analysis of the clinicopathologic 
findings for the recurrence group and for the non-recurrence 
group. The location of the tumor (P = 0.009), T stage (P = 0.010) 
and gross finding (P = 0.017) were found to be significant in the 
univariate analysis of the clinicopathologic factors affecting recur-
rence. A multivariate analysis was conducted on the clinicopatho-
logic factors found to be significant in the univariate analysis, and 
the gross finding of the tumor (P = 0.020) was identified as an in-
dependent factor affecting recurrence. Table 4 presents the post-
operative oral immunochemotherapy and clinicopathologic find-
ings for the recurrence group and the non-recurrence group. It 
shows that postoperative oral immunochemotherapy had no sta-
tistically significance relation to recurrence. The pathology slides 
of the patients experiencing recurrence were analyzed again by 
another pathologist for the presence of tumor cell budding, which 
was found in all the patients experiencing recurrence (Fig. 1).
Table 4. Univariate and multivariate analysis of postoperative oral immunochemotherapy 
Variable
PICTx (+) (n = 189, 45.3%) PICTx (-) (n = 245, 54.7%)
Without  
recurrence  
(n = 177)
With  
recurrence  
(n = 12)
Univariate  
P-value
Without  
recurrence  
(n = 237)
With  
recurrence  
(n = 8)
Univariate  
P-value 
Multivariate  
P-value
Age (yr) 0.785 0.001 0.946
   <65  143   9 129 0
   ≥65    46   3 116 8
Sex 0.822 0.582
   Male   97   6 143 4
   Female   80   6   94 4
CEA (ng/mL) 0.527 <0.001 0.066
   <6  163 11 219 4
   ≥6   26   1   26 4
Location  0.507 0.026 0.951
   Colon   47   2   96 0
   Rectum 130 10 141 8
T stage  0.462 0.018 0.744
   T1     8   0 123 1
   T2 169 12 114 7
Size (cm) 0.837 0.206
   <4    83   6 159 4
   ≥4   94   6   78 4
Growth  0.053 0.052
   B-I/II 157   9 216 6
   B-III/IV   20   3   21 2
Differentiation  0.296 0.082
   WD/MD 172 11 231 7
   PD/SRC     5   1     6 1
LVi  0.788 0.540
   No 153 10 220 7
   Yes   24   2   17 1
PICTx, postoperative oral immunochemotherapy; CEA, carcinoembryonic antigen; B-I/II, Bormann type-fungating/ulcerofungating; B-III/IV, Bormann type-ulceroinfiltrative/
infiltrative; WD, well-differentiated; MD, moderately differentiated; PD, poorly differentiated; SRC, signet ring cell carcinoma; LVi, lymphovascular invasion. 
Regimen of postoperative oral immunochemotherapy: single or combination therapy of oral chemotherapy agent (tegafur/uracil or doxifluridine) and immune modulator 
(polysaccharide-K) for 3 to 12 months.
Univariate analysis, Kaplan-Meier; multivariate analysis, Cox regression.Journal of The Korean Society of
Coloproctology
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Table 5. Previous studies for stage I colorectal cancer
Author Journal (yr) No. of patients Recurrence (%) Risk factors
Willett et al. [8] Cancer (1992)   64     8 (12.5) T2, LVi
Sticca et al. [9] Cancer Invest (1996)   71   7 (10) T2
Blumberg et al. [7] J Am Coll Surg (1998) 211 22 (12) Male, BVi
Wichmann et al. [10] World J Surg (2002) 296 29 (10) T2, high CEA level
Present study 434 20 (4.6) Growth pattern        
LVi, lymphovascular invasion; BVi, blood vessel invasion; CEA, carcinoembryonic antigen.
DISCUSSION
The overall prognosis for stage I colorectal cancer shows an excel-
lent outcome of greater than 90% for the 5-year survival rate [3], 
but 10 to 13% of the patients still experience recurrence [7-10]. 
T2 stage tumor [8-10], lymphovascular invasion [7, 8], lower rec-
tal lesions [9], male sex [7], a poorly-differentiated carcinoma [7] 
and high preoperative carcinoembryonic antigen value [10] were 
identified as influential factors related to the recurrence of stage I 
colorectal cancer in previous studies. Table 5 summarizes the re-
sults of previous studies related to the recurrence of first-stage 
colorectal cancer and compares them with the results of this study.
In this study, infiltrative type on the gross finding was identified 
as an independent factor affecting the recurrence in stage I colorec-
tal cancer. An infiltrative type of colorectal cancer has been reported 
to have a significant effect on recurrence because it invades the 
pericolorectal fatty tissues and lymph nodes more rapidly than 
the fungating type [11-13]. Steinberg et al. [11] reported that among 
influential factors affecting the prognosis of colon cancer after 
surgical interventions, the relative risk was 0.52 (P = 0.004) when 
a fungating type of colorectal cancer existed on the gross finding. 
Manfredi et al. [12] reported that the relative risk of an infiltrative 
Fig. 1. Photomicrography of tumor cell budding. An isolated single 
cancer cell and a cluster composed of fewer than five cancer cells are 
identified at the invasive front of the tumor (H&E, × 200).
type of colorectal cancer was 1.2 times greater (P = 0.037) than 
that of a fungating type of colorectal cancer when it comes to dis-
tant recurrence.
The presence of tumor cell budding was found in the pathology 
slides of all 20 patients experiencing recurrence in this study. Tu-
mor cell budding is known to be related to metastasis to lymph 
nodes [14, 15] and lymphovascular invasion [16] in cases of a sub-
mucosal invasive colorectal carcinoma. Hase et al. [17] analyzed 
the prognosis of colorectal cancer for 663 patients having had a 
radical resection after classifying the grade of tumor cell budding 
into two groups and concluded that tumor cell budding was a pow-
erful prognostic factor because a significant difference in recur-
rence rates (71.1% vs. 22.2%, P < 0.005) and in 10-year survival 
rates (50.6% vs. 13.8%, P < 0.001) existed. Ueno et al. [18] estab-
lished their own criterion, named high-grade budding (>10 foci 
within a microscopic field of x250), and reported that high-grade 
budding was related to aggressive characteristics such as histologi-
cal grade, proper muscle invasion, lymph-node metastasis, growth 
patterns and vascular invasion. Classifying the grade of tumor cell 
budding of the patients experiencing recurrence in this study, high-
grade budding (as it was defined by Ueno et al.) was observed in   
8 cases (40%). Although the presence of tumor cell budding or 
high-grade budding was not found to be an influential factor af-
fecting the recurrence of the stage I colorectal cancer because the 
result of tumor cell budding of the non-recurrence group was not 
confirmed in this study, further studies regarding tumor cell bud-
ding are thought to be required because the finding of tumor cell 
budding is judged to be related to the growth patterns and the his-
tological grade of the tumor.
When a univariate analysis for the characteristics of recurrence 
according to the location of the primary tumor, rectal cancer showed 
a higher recurrence rate than colon cancer (6.6% vs. 1.4%, P = 
0.009). Although no significant difference between the recurrence 
rate at the upper rectum and at the lower rectum in rectal cancer 
was noted, 17 cases (90%) among 19 cases of recurrent rectal can-
cer were located in the middle and in the lower rectum, indicating 
the characteristics of recurrence were different between the two 
locations. T stage tumors are known to be an independent factor 
related to the recurrence of colorectal cancer, and T2 stage identi-
fied in stage I colorectal cancer patients has been reported to be 
an independent factor related to recurrence [10, 13, 19, 20]. In this Journal of The Korean Society of
Coloproctology
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study, T2 stage was not identified as a significant influential factor 
related to recurrence (P = 0.064). The reason for this is thought to 
be the number of the patients, and a more significant result should 
be gained with bigger samples in further studies. Male sex and lym-
phovascular invasion were also identified as risk factors related to 
recurrence of stage I colorectal cancer in previous studies, although 
significant statistical results were not obtained in this study. Male 
sex has been understood as a poor prognostic factor for a long time, 
and in recent years, it has been recognized more as an indepen-
dent poor prognostic factor in stage II and III rectal cancer [21]. 
Lymphovascular invasions have been reported as a poor prognos-
tic factor in colorectal cancer patients [22, 23]. The authors reported 
that the recurrence rate was significantly higher when lymphovas-
cular invasion was identified in sporadic colorectal cancer. Also, 
especially in recent studies, recurrence in systemic lymph nodes 
was significant [24]. About 80% of the recurrences after a radical 
resection in colorectal cancer usually occurs within 2 years [25-27]. 
However, only 8 cases of recurrence (40%) among the 20 cases in 
this study occurred within 2 years, 10 (50%) occurred between         
2 years and 5 years, and the remaining 2 occurred after 5 years. 
The median value of the time to recurrence was 33 months in this 
study, which was rather different from the results of existing stud-
ies (12 to 22 month) [25]. Aghili et al. [28], in a study addressing 
early and late recurrence of colorectal cancer, reported that 70% 
of the recurrences in colorectal cancer occurred at an early stage 
within 2 years and that the factors related to early recurrence were 
young age, invasion to proximal organs and Duke C stage. The 
relatively low early recurrence in this study was estimated to be 
related to the characteristics of the stage I colorectal cancer where 
invasion to the intestinal wall was limited to the proper muscle.
Hepatic metastasis was reported to be the most common metas-
tasis occurring within two years from the radical resection in stud-
ies analyzing the characteristics of recurrence, but after two years, 
pulmonary metastasis was most commonly seen and was reported 
as the most common distant metastatic lesion [25]. In this study, 
one recurrence case from left colon cancer was a hepatic metasta-
sis, and three out of the four cases of pulmonary metastasis from 
rectal cancer occurred within two years. Six out of the 7 cases of 
local recurrence from rectal cancer occurred after two years which 
was distinctive from the existing results showing similar local re-
currence rate over the time [25, 28]. Even though a statistically 
significant comparison was difficult as the size of the sample was 
small, this recurrence pattern of stage I colorectal cancer is thought 
to be related to the characteristics of stage I colorectal cancer where 
invasion is limited to the proper muscle.
Among the 434 patients, 189 underwent postoperative oral im-
munochemotherapy, but no statistical significance was attached 
to the way in which the treatment affected the recurrence. How-
ever, the conduct of the statistical analysis might have been lim-
ited because the surgeons decided on the method and the drug 
for the therapy by referencing the operation and the pathological 
finding when they chose the patients for the therapy.
In conclusion, although the recurrence rate of colorectal cancer 
is around 10%, it is rare for patients to survive longer than 5 years. 
According to the results in this study, stage I colorectal cancer pa-
tients with infiltrative type cancer on the gross finding and with 
high-grade tumor cell budding were identified as a high risk group, 
and this should be borne in mind during the follow-up. Moreover, 
longer follow-up is advised for the high-risk group with rectal can-
cer, T2 stage and infiltrative type, because, contrary to the recur-
rence patterns for stage II and III colorectal cancer, more than 
60% of the recurrences of stage I colorectal cancer occurred after 
2 years.
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